Your browser doesn't support javascript.
loading
Effect of High-Intensity Rosuvastatin vs. Combination of Low-Intensity Rosuvastatin and Ezetimibe on HbA1c Levels in Patients without Diabetes: A Randomized IDEAL Trial.
Choe, Jeongcheon; Lee, Sun-Hack; Ahn, Jinhee; Lee, Hyewon; Oh, Jun-Hyok; Choi, Junghyun; Lee, Hancheol; Cha, Kwangsoo; Park, Jinsup.
Affiliation
  • Choe J; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Lee SH; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Ahn J; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Lee H; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Oh JH; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Choi J; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Lee H; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Cha K; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
  • Park J; Department of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
J Clin Med ; 12(18)2023 Sep 21.
Article in En | MEDLINE | ID: mdl-37763042
There is a dearth of studies investigating whether the combination of low-intensity statins with ezetimibe can reduce the risk of diabetes in patients requiring statin therapy. Therefore, we aimed to evaluate the effects of combination therapy on the prevention of glycated hemoglobin (HbA1c) elevation in patients without diabetes. Sixty-eight patients were randomly assigned in a 1:1 ratio to receive a combination of low-intensity rosuvastatin (5 mg/day) and ezetimibe (10 mg/day) or high-intensity rosuvastatin (20 mg/day). The primary endpoint was the absolute difference in the HbA1c levels at 12 weeks. The HbA1c level showed an overall elevation of 0.11% at 12 weeks compared to that at baseline (mean ± standard deviation: 5.78 ± 0.3%, 95% confidence interval [CI]: 5.86-6.07, p = 0.044). The HbA1c levels did not differ between the groups at 12 weeks (least square mean difference: 0.001, 95% CI: 0.164-0.16, p = 0.999). Our study found that the combination of low-intensity rosuvastatin and ezetimibe did not yield significant differences in HbA1c levels compared to high-intensity rosuvastatin alone after 12 weeks in patients without diabetes. This suggests that the combination of low-intensity rosuvastatin and ezetimibe may not be an effective strategy for preventing HbA1c elevation in patients without diabetes requiring statins.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Clin Med Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Clin Med Year: 2023 Document type: Article Country of publication: